A Multicentre, Retrospective Study to Evaluate the Outcome of HSCT Mismatch Unrelated Donors

Study to Evaluate the Outcome of HSCT Mismatch Unrelated Donors

The primary endpoint of the study was the acute GvHD incidence, the secondary endpoints were chronic GvHD incidence, overall survival (OS), transplant related mortality (TRM) incidence, relapse incidence (RI) and neutrophil and platelets engraftment after GvHD prophylaxis with ATG-CSA-MTX or PTCy-MMF-FK506

Inclusion Criteria:

• children and adults)
• HSCT from a one-antigen mismatch unrelated donors
• Treated at the Centro Trapianti Metropolitano di Torino between 2012 to 2017

Exclusion Criteria: none